Запорожский Государственный Медицинский Университет
Иван Михайлович Билай
Евгений Сергеевич Пругло
Андрей Григорович Каплаушенко
Андрей Сергеевич Гоцуля
Александр Иванович Панасенко
Евгений Григорович Книш
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Запорожский Государственный Медицинский Университет, Иван Михайлович Билай, Евгений Сергеевич Пругло, Андрей Григорович Каплаушенко, Андрей Сергеевич Гоцуля, Александр Иванович Панасенко, Евгений Григорович КнишfiledCriticalЗапорожский Государственный Медицинский Университет
Priority to UAU200903532UpriorityCriticalpatent/UA43391U/en
Publication of UA43391UpublicationCriticalpatent/UA43391U/en
1-(3-(6,7-dimethoxyquinazolin-4-yloxy)phenyl)-3-(5-(1,1,1-trifluoro- 2-methylpropan-2-yl)isoxazol-3-yl)urea as raf kinase modulator in the treatment of cancer diseases raf 1-(3-(67--4- ))-3-(5-(111--2--2-)-3-)
Morpholinium 2-(5-(4-pyridyl)-4-(2-methoxyphenyl)-1,2,4-triazole-3-ylthio)acetate having antihypoxic activity with thermal protective properties and dosage forms thereof
Method for preparing 5-chloro-n-({(5s)-2-oxo-3-[4-(5,6-dihydro-4h-[1,2,4]triazin-1-yl)phenyl]-1,3-oxazolidin-5-yl}methyl)thiophen-2-carboxamide derivative and intermediate used therein